(Q37405140)

20 August 2017

1 reference

title

The impact of pharmacogenetics on HIV therapy (English)

1 reference

20 August 2017

0 references

A Owen

3

0 references

author name string

T W Mahungu

series ordinal

1

1 reference

20 August 2017

M A Johnson

series ordinal

2

1 reference

20 August 2017

D J Back

series ordinal

4

1 reference

20 August 2017

publication date

1 March 2009

1 reference

International Journal of STD & AIDS

20 August 2017

published in

1 reference

20 August 2017

volume

20

1 reference

20 August 2017

issue

3

1 reference

20 August 2017

page(s)

145-151

1 reference

Determinants of virological response to antiretroviral therapy: implications for long-term strategies

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Human inter-individual DNA sequence variation in candidate genes, drug targets, the importance of haplotypes and pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

HapMap, pharmacogenomics, and the goal of personalized prescribing

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

A haplotype map of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Metabolism of Zidovudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Mechanism of active renal tubular efflux of tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment--case report and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Fanconi syndrome and renal failure induced by tenofovir: a first case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Substrates of human hepatic cytochrome P450 3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

A manic episode associated with efavirenz therapy for HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Efavirenz-induced catatonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Management of sudden psychiatric disorders related to efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Higher efavirenz plasma levels correlate with development of insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring?

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Successful use of reduced-dose efavirenz in a patient with human immunodeficiency virus infection: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Incidence and risk factors for nevirapine-associated rash

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Mechanism-based inactivation of CYP3A by HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

A review of low-dose ritonavir in protease inhibitor combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Protein binding in antiretroviral therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

A "silent" polymorphism in the MDR1 gene changes substrate specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Apolipoprotein E: far more than a lipid transport protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Mechanism of indinavir-induced hyperbilirubinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

Drug Transporter and Metabolizing Enzyme Gene Variants and Nonnucleoside Reverse-Transcriptase Inhibitor Hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008369

21 January 2018

Identifiers

DOI

10.1258/IJSA.2008.008369

1 reference

20 August 2017

1 reference